PMAD Prevalence in Primary Care: Why Your Panel Has More Cases Than You Think

Perinatal mood and anxiety disorders (PMADs) are the most common complication of childbirth, affecting approximately 1 in 5 birthing patients. For family medicine and internal medicine clinicians, the implication is straightforward: if you provide primary care to women of reproductive age, PMAD cases are sitting in your schedule whether or not you are identifying them.

The numbers most PCPs underestimate

Pooled prevalence data from ACOG, AAP, and the USPSTF converge on the following figures:

• Postpartum depression: 10 to 15 percent of birthing patients, with major depressive episodes confirmed in approximately 7 percent
• Antenatal depression: 7 to 13 percent during pregnancy
• Perinatal anxiety disorders (GAD, panic, OCD, PTSD): 15 to 20 percent, with significant overlap with depression
• Postpartum psychosis: 1 to 2 per 1,000 deliveries, requiring same-day psychiatric evaluation

When anxiety and depression are counted together, conservative estimates put the perinatal mental illness rate at 20 percent. Some primary care cohorts report rates above 25 percent once subclinical and mixed presentations are included.

Translating prevalence to your panel

Consider a family medicine clinician with a panel of 1,500 patients. If 30 percent are women aged 18 to 44, that is roughly 450 patients. Assuming 8 percent are pregnant or postpartum in any given year, the panel contains around 36 perinatal patients annually. At a 20 percent PMAD prevalence rate, that is 7 active cases per year, per clinician, in primary care alone.

For a five-clinician practice, this scales to 35 active perinatal mental health cases annually. Most practices identify and document fewer than half of these.

Why prevalence is invisible without screening

PMADs rarely present with the chief complaint "I think I have postpartum depression." More common presentations in the 15-minute primary care visit:

• Persistent insomnia despite the infant sleeping
• Fatigue out of proportion to the postpartum recovery timeline
• New or worsening headache, GI distress, or chest tightness
• Vague concerns about weight, appetite, or libido
• Frequent infant-related visits driven by maternal anxiety rather than infant pathology

These presentations route patients into somatic workups: TSH, CBC, ferritin, vitamin D, sometimes imaging. The workup is often negative, the patient is reassured, and the underlying mood or anxiety disorder remains undiagnosed.

Subgroups with elevated risk

Several populations within a typical primary care panel carry substantially higher PMAD risk and warrant a lower threshold for screening:

• Patients with prior depression, anxiety, or trauma history (lifetime prior diagnosis doubles risk)
• Patients with pregnancy loss, fertility treatment, or obstetric complications
• NICU parents (rates of acute stress disorder and PTSD up to 40 percent)
• Patients with limited social support or financial stress
• Black, Hispanic, and Indigenous patients, who have higher prevalence and lower diagnosis rates
• Patients with chronic medical conditions including diabetes, autoimmune disease, and thyroid disorders

What the screening gap costs

Untreated perinatal depression carries documented downstream consequences relevant to primary care: impaired infant attachment, delayed pediatric well-child attendance, increased ED utilization, worsened chronic disease control, and elevated suicide risk. Maternal suicide is now a leading cause of pregnancy-associated death in the United States, exceeding obstetric hemorrhage in several state maternal mortality reviews.

The case for systematic screening is not about adding another quality metric. It is about recognizing that the prevalence is already in your panel, and the only question is whether you are capturing it.

Coding patterns that obscure prevalence

Even practices that suspect they have a detection gap often underestimate it because their problem-list data does not reflect reality. Common coding habits that hide PMAD volume in primary care:

• Defaulting to F32.9 (unspecified depression) rather than F53.0 (postpartum depression) or O90.6 (postpartum mood disturbance), which removes the perinatal flag from population health reports
• Using R45.82 (worries) or R45.0 (nervousness) as placeholders when a clinician suspects anxiety but does not formally diagnose
• Omitting Z codes for psychosocial stressors that contextualize the presentation, such as Z63.0 or Z65.8
• Recording symptoms (insomnia, fatigue) as standalone diagnoses rather than as features of an underlying mood or anxiety disorder

A practice running a problem-list query restricted to F53.0 will find a fraction of its true PMAD volume. Querying broader F32, F33, F41, F42, and F43 codes within a 12-month postpartum window gives a more accurate denominator.

Practical next steps

1. Audit your practice's perinatal volume. Pull a count of patients with pregnancy or delivery codes in the past 12 months.
2. Review your current screening rate. If you are not running EPDS or PHQ-9 at prenatal and postpartum visits, your detection rate is below 50 percent.
3. Identify your referral pathway in advance. Knowing prevalence is only useful if you have a specialist to refer to when a screen is positive.
4. Coordinate with local pediatric practices. The AAP recommends maternal depression screening at well-child visits through the first year, which gives your patients additional touchpoints and your practice a second source of detection signal.

Reimbursement context for systematic screening

Systematic PMAD screening in primary care is reimbursable, which matters for practice sustainability. The USPSTF B recommendation for perinatal depression screening makes the service eligible for ACA preventive coverage without cost-sharing in most commercial plans. CPT 96127 (brief emotional/behavioral assessment) covers screener administration, and most Medicaid managed care contracts include it. For practices billing under a global OB care model, coordination with the obstetric team on who bills for which screening encounter avoids duplication.

Practices using population health platforms can also capture value-based care credit for PMAD screening completion rates. HEDIS does not currently include a perinatal depression screening measure at the adult primary care level, but several commercial payer quality programs track it as a supplemental metric. Documenting the screening tool, score, and follow-up action in a structured field rather than free text is a prerequisite for any of these reporting pathways.

What this means for panel management

Population health teams that incorporate perinatal mental health into routine quality dashboards see two operational shifts within the first year. First, the documented PMAD case count rises sharply, often doubling or tripling, which is a feature of accurate measurement and not a sign of worsening prevalence. Second, downstream utilization patterns become legible: ED visits for somatic complaints decline, no-show rates for postpartum and well-woman visits fall, and pediatric well-child attendance improves in the panels of identified patients. These are measurable wins that justify the screening infrastructure to practice leadership and payers.

The takeaway for primary care is direct. PMAD prevalence in your panel is higher than the cases you have documented, and the gap is closeable with structured screening and a known referral pathway.